National trends and predictors of 90-day all-cause readmission in hepatocellular carcinoma: A real-world outcomes study using the Nationwide Readmissions Database.

491 Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer related mortality. Outcomes are often shaped not only by the cancer itself but also by the burden of underlying cirrhosis and treatment related complications. Hospitalizations are common and carry substantial costs, driven by both disease progression and liver decompensation. This study examines resource use and the leading causes of 90-day readmissions after HCC admissions. Methods: We conducted a retrospective study using the 2022 Nationwide Readmissions Database (NRD), part of the Healthcare Cost and Utilization Project. We identified patients with Hepatocellular carcinoma who were hospitalized between January and October. The first unplanned readmission within 90 days of discharge was used to define the readmission cohort. Survey-weighted logistic, linear, and Cox regression models were used to assess clinical and hospital-level factors associated with readmission. Results: In multivariable analysis, younger age (aHR 0.99, p